Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
CanSino Biologics

CanSino Biologics

CanSino Biologics (CanSinoBIO) is a bio pharmaceutical company primarily producing vaccines.

Established in Tianjin, China in 2009, CanSino Biologics (CanSinoBIO) has 450 employees. They currently have 15+ vaccines in their pipeline. Some in pre-clinical, some in NDA (new drug application). These include; meningitis, pneumonia, tuberculosis, Ebola virus disease, pertussis, diphtheria, tetanus, shingles etc. Since March of 2019, CanSino Biologics has been listed on the Hong Kong Exchange (HKEx). The annual bulk production capacity of the facilities as of 2020 can reach approximately 70 million to 80 million doses.

COVID-19 response

CanSino Biologics, announced in March 2020 that it was close to testing its novel coronavirus vaccine in a clinical trial in China. CanSino’s approach involves taking part of coronavirus’ genetic code and entwining it with a virus, thereby exposing healthy volunteers to the novel infection and spurring the production of antibodies. CanSino also markets a vaccine for Ebola virus in China.

In April 2020, CanSino Biologics advanced its vaccine candidate candidate, Ad5-nCoV, into Phase II trials (Chinese registration number: ChiCTR2000030906). CanSino Biologics (CanSinoBIO) is collaborating with the National Research Council of Canada (NRC) to advance bioprocessing and clinical development of vaccine candidate against COVID-19, Ad5-nCoV. Ad5-nCoV was co-developed by the Beijing Institute of Biotechnology (BIB) and CanSinoBIO. A genetically engineering replication-defective adenovirus type 5 vector was used to express the SARS-CoV-2 spike protein which is produced in HEK293 cell lines designed and developed at the NRC. As of May 12, 2020, the vaccine is subject to approval by Health Canada for a Clinical Trial Application being filed by CanSinoBIO. As a preparatory step the Government of Canada announced $44 million in funding to support upgrades to NRC facilities in Montreal to ensure readiness for Canadian bioprocessing of potential vaccine candidates.


April 19, 2017
CanSino Biologics raises a $65,000,000 series E round from Fortune Capital, Goldstone Financial Group, Gopher Asset Management, Lilly Asia Ventures, QiMing Venture Partners and SDIC Fund Management Company.
April 1, 2016
CanSino Biologics raises a $11,000,000 venture round from QiMing Venture Partners.
November 3, 2015
CanSino Biologics raises a $30,000,000 series C round from Lilly Asia Ventures and Qiming Venture Partners.
September 16, 2013
CanSino Biologics raises a $10,000,000 venture round from Lilly Asia Ventures.
CanSino Biologics was founded by Dongxu QIU, PhD, Tao ZHU, PhD and Xuefeng YU, PhD.

Funding Rounds



Further Resources



May 24, 2021
Forbes India
Critics say the decision will deepen the divisions within the country, where a large section of the society lives under the poverty line
Salman Masood
May 22, 2021
An inoculation push, plagued with limited supplies and red tape, makes doses available to those who can pay for them. In a country with a struggling economy, most can't.
Tom Blackwell
August 4, 2020
Samples of the vaccine candidate have not been approved for shipment to Canada by Chinese customs, one of the researchers confirmed Tuesday
Financial Times
September 24, 2020
Out of 300 candidates, nine are in phase 3 trials, with some hoping for emergency use approval this year
Andrew Dunn
November 9, 2020
Business Insider
There are 45 potential coronavirus vaccines now in human testing, with the frontrunners eyeing potential emergency approval as soon as November.


Golden logo
By using this site, you agree to our Terms & Conditions.